Surmodics Announces Appointment of Timothy J. Arens as Chief Financial Officer
February 18 2019 - 8:30AM
Business Wire
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of
medical device and in vitro diagnostic technologies to the
healthcare industry, today announced the appointment of Timothy J.
Arens, Vice President of Corporate Development and
Strategy, as the company’s new Chief Financial Officer (CFO),
effective immediately.
Arens was named interim CFO in May 2018 following the departure
of Andrew LaFrence. Arens’ corporate development and strategy
responsibilities will be absorbed into his CFO role.
“Tim has been an impressive partner to me and an invaluable
contributor to our management team and Surmodics’ success during
the past eight years. I am personally delighted that he has been
formally appointed to the role,” said Gary Maharaj, President and
Chief Executive Officer of Surmodics. “Tim's excellent
financial, operational and strategic skills and strong leadership
are ideally suited to his new role as we continue to drive our
strategic initiatives and financial goals of consistent and
profitable long-term growth."
Arens has served in his current role since February 2013. He
joined Surmodics in February 2007 as Director, Business
Development, was named Senior Director and General Manager of the
in vitro diagnostics business unit in October 2010 and served as
Vice President of Finance and interim CFO from August 2011 to
February 2013.
“I am excited to work with a group of dedicated and talented
colleagues to accelerate our strategic transformation while
continuing to deliver on our operating commitments,” said Arens.
“Surmodics is well-positioned to execute on our strategic
initiatives including the development of highly innovative products
that benefit patients. I am looking forward to being part of that
journey.”
About Surmodics, Inc.
Surmodics is the global leader in surface modification
technologies for intravascular medical devices and a leading
provider of chemical components for in vitro diagnostic immunoassay
tests and microarrays. Surmodics is pursuing highly
differentiated whole-product solutions that are designed to address
unmet clinical needs for its medical device customers and
engineered to the most demanding requirements. This key growth
strategy leverages the combination of the Company’s expertise in
proprietary surface technologies, along with enhanced device
design, development and manufacturing capabilities. The Company
mission remains to improve the detection and treatment of disease.
Surmodics is headquartered in Eden Prairie, Minnesota. For more
information, visit www.surmodics.com. The content of Surmodics’
website is not part of this press release or part of any filings
that the company makes with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements.
Statements that are not historical or current facts are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and important factors could cause
actual results to differ materially from those anticipated,
including the factors identified under “Risk Factors” in Part I,
Item 1A of our Annual Report on Form 10-K for the fiscal year
ended September 30, 2018, and updated in our subsequent
reports filed with the SEC. These reports are available in the
Investors section of our website at www.surmodics.com and
at the SEC website at www.sec.gov. Forward-looking
statements speak only as of the date they are made, and we
undertake no obligation to update them in light of new information
or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190218005037/en/
Surmodics, Inc.Tim Arens, 952-500-7000ir@surmodics.com
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Apr 2023 to Apr 2024